Omalizumab (rhuMAb-E25)

Omalizumab (rhuMAb-E25)

Self surveys the current evidence on the effectiveness and safety of omalizumab for treating asthma that is refractory to conventional long-term management.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Formulary (Cleveland, Ohio) Ohio), 2001-08, Vol.36 (8), p.571
Hauptverfasser: Self, Timothy H, James, Alan W, Finch, Christopher K
Format: Artikel
Sprache:eng
Schlagworte:
Allergens
Allergies
Antigens
Asthma
Clinical trials
Drug dosages
Drug therapy
Inflammation
Monoclonal antibodies
Patients
Pharmacokinetics
Rhinitis
Statistical significance
Steroids
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Self surveys the current evidence on the effectiveness and safety of omalizumab for treating asthma that is refractory to conventional long-term management.
ISSN:1082-801X
1938-1166